Brought to you by 
Grifols divests some Talecris assets to Kedrion SPA
18 Nov 2022
Executive Summary
To satisfy FTC merger conditions associated with its pending acquisition of Talecris Biotherapeutics Inc. (signed in 2010), Grifols SA has agreed to the sale of some of Talecris’s assets to Italian plasma production company Kedrion SPA.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Manufacturing or Supply
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Grifols divests some Talecris assets to Kedrion SPA
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice